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associated with SARS-CoV-2 infection:
integrative concepts of pathophysiology
and case reports
Souhel Najjar1,2*, Amanda Najjar1,3, Derek J. Chong1, Bidyut K. Pramanik4, Claudia Kirsch5, Ruben I. Kuzniecky1,
Steven V. Pacia1,2 and Salman Azhar1

Abstract
Coronavirus disease 2019 (COVID-19) is a highly infectious pandemic caused by a novel coronavirus called severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It frequently presents with unremitting fever, hypoxemic
respiratory failure, and systemic complications (e.g., gastrointestinal, renal, cardiac, and hepatic involvement),
encephalopathy, and thrombotic events. The respiratory symptoms are similar to those accompanying other
genetically related beta-coronaviruses (CoVs) such as severe acute respiratory syndrome CoV (SARS-CoV) and Middle
East Respiratory Syndrome CoV (MERS-CoV). Hypoxemic respiratory symptoms can rapidly progress to Acute
Respiratory Distress Syndrome (ARDS) and secondary hemophagocytic lymphohistiocytosis, leading to multi-organ
system dysfunction syndrome. Severe cases are typically associated with aberrant and excessive inflammatory
responses. These include significant systemic upregulation of cytokines, chemokines, and pro-inflammatory
mediators, associated with increased acute-phase proteins (APPs) production such as hyperferritinemia and elevated
C-reactive protein (CRP), as well as lymphocytopenia. The neurological complications of SARS-CoV-2 infection are
high among those with severe and critical illnesses. This review highlights the central nervous system (CNS)
complications associated with COVID-19 attributed to primary CNS involvement due to rare direct neuroinvasion
and more commonly secondary CNS sequelae due to exuberant systemic innate-mediated hyper-inflammation. It
also provides a theoretical integration of clinical and experimental data to elucidate the pathogenesis of these
disorders. Specifically, how systemic hyper-inflammation provoked by maladaptive innate immunity may impair
neurovascular endothelial function, disrupt BBB, activate CNS innate immune signaling pathways, and induce parainfectious autoimmunity, potentially contributing to the CNS complications associated with SARS-CoV-2 infection.
Direct viral infection of the brain parenchyma causing encephalitis, possibly with concurrent neurovascular
endotheliitis and CNS renin angiotensin system (RAS) dysregulation, is also reviewed.
Keywords: SARS-CoV-2, COVID-19, ACE2, Endothelial cells, Blood-brain barrier, Cytokines, Microglia, Encephalitis,
Encephalopathy, Stroke
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Background
Coronavirus disease 2019 (COVID-19) is a highly infectious pandemic caused by a novel coronavirus called
severe acute respiratory syndrome coronavirus 2 (SARSCoV-2). It frequently presents with unremitting fever,
hypoxemic respiratory failure, and systemic complications
(e.g., gastrointestinal, renal, cardiac, and hepatic involvement), encephalopathy, delirium, and thromboembolic
events [1–6]. Hypoxemic respiratory symptoms can rapidly progress to Acute Respiratory Distress Syndrome
(ARDS) and secondary hemophagocytic lymphohistiocytosis, leading to multi-organ system dysfunction syndrome
[1–6]. Higher severity and mortality rates occur in the
older population especially for those with an immunecompromised state and co-morbidities including hypertension, diabetes, cardiovascular disease, obesity, and
chronic obstructive lung disease [6–9]. Early reports estimated the mortality rate to be about 37% among hospitalized individuals with COVID-19 infection [9, 10]. Severe
cases are typically associated with aberrant and excessive
inflammatory responses [1, 5, 6, 11]. These are reflective
of acute innate immunity activation (i.e., cytokines,
chemokines, and pro-inflammatory mediators), associated
with increased acute-phase protein (APP) production (i.e.,
hyperferritinemia and elevated C-reactive protein (CRP)),
and lymphocytopenia [1, 6, 7, 11–13]). The affected
lymphocyte subsets are CD4+ T cells (memory, effector,
and regulatory), CD8+ T cells, B cells, and natural killer
(NK) cells [14]. Greater circulating TH17 counts were associated with worse clinical outcomes [14]. Although
many cytokines and chemokines can be elevated in the
sera of individuals infected with SARS-CoV-2 infection,
certain cytokines and chemokines (i.e., interleukin (IL)-1β,
IL-2, IL-6, IL-7, IL-10; tumor necrosis factor-α (TNF)-α;
granulocyte-colony stimulating factor (G-CSF); granulo
cyte-macrophage colony stimulating factor (GM-CSF);
CXCL10, formerly known as interferon-γ inducible protein 10 (IP-10); CCL2, formerly known as monocyte
chemoattractant protein 1 (MCP-1), and CCL3, formerly
known macrophage inflammatory protein [MIP]-1α), were
higher in severe cases [5–7, 11–13, 15, 16] (Fig. 1), such as
those in ICU patients compared to those in non-ICU.
Further, persistent elevation of serum levels of CXCL10,
CCL7 (MCP-3), and IL-1 receptor antagonist was
associated with greater viral load and worse clinical
outcome [17].
This review highlights the central nervous system (CNS)
complications associated with SARS-C0V-2 infection that
involve primary CNS involvement due to rare direct
neuroinvasion and more commonly secondary CNS
sequelae due to exuberant systemic innate-mediated
hyper-inflammation. It also provides a theoretical integration of clinical and experimental data to elucidate the
pathogenesis of these disorders. Specifically, how systemic
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hyper-inflammation provoked by maladaptive innate
immunity may impair neurovascular endothelial function,
disrupt BBB, activate CNS innate immune signaling pathways, and induce para-infectious autoimmunity, potentially contributing to the CNS complications associated
with SARS-CoV-2 infection. Direct viral infection of the
brain parenchyma causing encephalitis, possibly with
concurrent neurovascular endotheliitis and CNS renin
angiotensin system (RAS) dysregulation, is also reviewed.

Neurological disorders associated with SARS-CoV2
CoVs-seropositivity is reported in association with
several neurological disorders with diverse immuneinflammatory processes such as acute disseminated
encephalomyelitis (ADEM)-like demyelination, multiple
sclerosis, optic neuritis, and encephalitis [18–21]. The
capacity for neurovirulence in coronaviruses, including
SARS-CoV-2, may contribute to the relatively high
prevalence of neurological complications in COVID-19
patients [22–25], particularly among hospitalized
patients with severe or critical illnesses [10, 26]. Early
reports estimated the incidence of neurological complications to be about 37% [10, 26–32]. These complications were more common among severe cases associated
with greater acute innate immune-inflammatory response (e.g., pro-inflammatory cytokines, chemokines),
higher levels of CRP, ferritin, and D-dimer [7, 8, 10, 12,
31, 33]. Of note, like in many other viral infections and
para-infectious diseases, an increase in neutrophil and
decrease in lymphocyte counts were associated with
greater disease severity and poorer clinical outcome [14,
33]. Notably, the severity of lymphocytopenia correlates
negatively with a rise in serum levels of IL-6, TNF-α,
and IL-10, and positively with disease progression and activity [34], and upregulation of T cell exhaustion markers
[14, 34]. The exhaustion markers are T cell immunoglobulin and mucin domain-containing protein-3 (TIM-3)
(mainly expressed on activated CD4+ Th1 cells and CD8+
cytotoxic T cells) [35], programmed cell death-1 (PD1)
(mostly expressed on activated CD4+ T cells and CD8+ T
cells [35]). CD94/NK group 2 member A (NKG2A) mainly
expressed on cytotoxic lymphocytes such as NK cells and
CD8+ T cells [14]. The concurrent upregulation of these
markers suggests that the aberrantly upregulated cytokines promoted lymphocytopenia via depleting functionally exhausted T cells [14, 34]. The normalization of
lymphocyte count, together with the reversal of T cell
functional exhaustion, adds support for the contribution
of aberrant cytokine production to lymphocyte death [14].
Moreover, post-mortem examination of COVID-19positive subjects revealed atrophy and necrosis of the
spleen and lymph nodes, together with lymphocytic
apoptosis [36]. SARS-CoV-2 nucleoprotein antigen was
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Fig. 1 Integrative concepts of the pathophysiology of COVID-19-related central nervous system complications. This figure integrates the clinical
and experimental data linking maladaptive innate immunity-related systemic hyper-inflammation (provoked by the binding of SARS-CoV-2 spike
protein (S1) to ACE2 expressing cells in the lung and intestine) to neurovascular endothelial dysfunction, BBB breakdown, and CNS innate
immune activation, potentially contributing to SARS-CoV-2-related CNS complications. It demonstrates subsequent endothelial injury in the
peripheral vasculature due to direct viral endothelial infection causing endotheliitis and potential endothelial ACE2 downregulation: similar
mechanisms may also involve neurovascular unit. It also depicts the proposed role of infiltrating protective immune cells, migrating from the
bloodstream into the CNS parenchyma through disrupted BBB, in limiting CNS injury and promoting viral clearance. ACE, angiotensin-converting
enzyme; ACE2, angiotensin-converting enzyme II; AT type 1 receptor, angiotensin type 1 receptor; BBB, blood-brain barrier; CNS, central nervous
system; G-CSF, granulocyte colony stimulating factor; GM-CSF, granulocyte-macrophage colony stimulating factor; IL, interleukin; MAP, microglial
activation and proliferation; MMPs, matrix metalloproteinases; NK, natural killer; PRRs, pattern recognition receptors, SARS CoV-2 (S1), severe acute
respiratory syndrome coronavirus 2 (spike glycoprotein1), receptor-binding subunit; TNFα, tumor necrosis factor-α

detected in angiotensin converting enzyme 2 (ACE2)-expressing CD169+ macrophages present in the marginal
zone of the spleen and in the subcapsular sinuses of the
lymph nodes [36]. These macrophages exhibited significant IL-6 upregulation. These findings suggest the infected macrophages can, via IL-6 upregulation, promote
viral spread, inflammation, and lymphocyte depletion [36].
Lymphocytic apoptosis together with the pattern of cytokine and chemokine upregulation reflective of the innate
immune response indicate that SARS-CoV-2 infection
primarily involves uncontrollable activation of innate

immune cells (mainly neutrophils and macrophages) while
impairing cells mediating adaptive immunity (i.e., CD4+ T
cells, CD8+ T cells, B cells, and NK cells) [14]. This can be
pathogenetically relevant as these adaptive immune cells
can exert immunoprotective effects to regulate harmful
inflammation, protect uninfected host cells, and facilitate
viral clearance [1, 14].
The neurological manifestations can be generally
divided into two categories: central and peripheral [10,
23, 26–30, 37–41]. Central manifestations include headache, dizziness, impaired consciousness, encephalopathy,
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delirium, global confusion, syncope, seizures, gait
difficulties, cerebrovascular events, encephalitis, and
post-infectious autoimmunity. Peripheral disorders include isolated cranial nerve dysfunctions (i.e., impaired
sense of smell and taste sensation), Guillain-Barré-syndrome, and myositis-like muscle injury. Although the
majority of neurological symptoms develop throughout
the course of illness, others such as acute strokes can be
the initial presentation [10]. In this review, we focus only
on the pathophysiology of the CNS complications in
COVID-19.

Encephalopathy and delirium; role of systemic
hyper-inflammation
Encephalopathy is commonly reported in SARS-CoV-2
infection [32]. The etiology is often multifactorial and
includes hypoxic respiratory distress, toxic-metabolic
disturbances, medication effects, sepsis with multi-organ
dysfunction/failure, seizures/postictal state, and immune
dysregulation.
Additionally, our experience, as well as that of other
centers [32, 38], suggests that hospitalized SARS-CoV-2positive individuals display a distinctive, but common,
form of encephalopathy associated with systemic hyperinflammation mainly provoked by an aberrantly excessive innate immune response. It is characterized by
global brain dysfunction with a reduced level of alertness
and consciousness, often in association with overactive
delirium and agitation or alternatively severe psychomotor retardation with abulia and catatonia-like state.
At times, it rapidly progresses to a persistent coma state
that cannot be fully unexplained by ongoing seizures or
prolonged postictal state, metabolic abnormalities, or
medication effects. It is often more intense, has more
overt neuropsychiatric features (e.g., delusions, agitation,
mood changes, and irritability), and is generally less responsive to traditional antipsychotics, as compared to
the common spectrum of encephalopathies in critical
illness [32]. Onset is frequently concurrent with a rapid
increase in serum levels of APPs (e.g., CRP and ferritin;
produced primarily by hepatocytes in response to diverse
pro-inflammatory cytokines, predominantly IL-6, and
IL-1β) [39]. Notably, cerebrospinal fluid (CSF) analysis is
either normal or shows mildly to moderately elevated
protein level without pleocytosis, despite the abnormal
leptomeningeal enhancement reported in some cases
[32]. This might be explained by the concurrent lymphocytopenia, involving T cells and B cells, caused by
lymphocytic apoptosis induced by viral replicationrelated hypercytokinemia [1, 14, 33, 34]. Thus, the absence of CSF pleocytosis does not exclude the possibility
of an inflammatory process. Reverse transcriptase–polymerase-chain-reaction (RT-PCR) assay for SARS-CoV-2
in CSF samples was negative in the majority of reported
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cases with severe neurological complications [32]. This
suggests that the majority of the SARS-CoV-2-related
neurological complications are likely not related to
direct viral entry into the CNS. However, the potential
contribution of diagnostic pitfalls, such as false-negative
testing that might occur early in the disease course when
CSF viral load may be insufficient for detection by RTPCR assay, cannot be excluded. Electroencephalogram
(EEG) typically shows diffuse slowing corresponding to
the severity of encephalopathy, with or without triphasic
waves. Neuroimaging can be normal or display nonspecific abnormalities, such as regional hypoperfusion
[32] (Fig. 1), scattered punctate diffusion restriction (Fig.
2), T2-shine through, and focal enhancement [32], which
can present diagnostic and therapeutic dilemmas.
We suggest that the pathophysiology is likely related to
aberrant CNS innate immune signaling pathways in response to the peripheral hyper-inflammation provoked by
surges in pro-inflammatory cytokines [4]. Pro-inflammatory
cytokines can disrupt blood-brain barrier (BBB) and increase its permeability (Fig. 1) [40–43]. IL-1β, IL-6, TNFα,
and IL-17 are among the main effector cytokines shown experimentally to increase BBB permeability (see cytokines
and BBB hyperpermeability section) (Fig. 1) [40–43]. Entry
of pro-inflammatory cytokines in the CNS can activate glial
cells and alter their functions, leading to microglial activation and proliferation (MAP) [44]. MAP can further disrupt
the functional and structural integrity of BBB (Fig. 1). For
example, animal studies showed that MAP could
disintegrate endothelial tight junction proteins via several
mechanisms [43, 45] including releasing pro-inflammatory
cytokines and chemokines, upregulating inducible proinflammatory molecules such as matrix metalloproteinase
(MMPs) among others, and promoting oxidative stress (Fig.
1) [40, 41, 45]. BBB breakdown, in turn, can potentially
facilitate deleterious crosstalk between brain innate and
peripheral adaptive immunity, thereby creating a selfperpetuating neuroinflammatory milieu [40, 41, 43]. This
milieu can exert negative influence on neurotransmission
and cause glutamate-mediated neuronal excitotoxicity [46,
47]. It can also damage neurovascular endothelium [42, 45,
48] and impair endothelial nitric oxide synthase (eNOS)dependent vasodilation [40, 41]. Reduced vasodilation and
loss of endothelial dynamic autoregulatory capacity can decrease cerebral perfusion [48]. Clinically, this is supported
by the frequent finding of non-specific punctate foci of
restricted diffusion on diffusion-weighted imaging (DWI)
(Fig. 2) and cerebral hypoperfusion on perfusion imaging in
COVID-19 infection with concurrent global encephalopathy (Figs. 1 and 2) [32]. Further, direct SARS-CoV-2
infection of the ACE2 expressing endothelia of the neurovascular unit causing endotheliitis and vascular injury,
which might also contribute to the cerebral hypoperfusion,
remains up to now unproven (Fig. 1). Combining medical
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Fig. 2 Seizure and malignant EEG pattern associated with rapid rise in serum CRP. A 71-year-old SARS-CoV-2 positive female presented with
altered mental status necessitating intubation. While on sedation, she was witnessed to have a convulsive seizure, with CRP elevating from 16.64
to 30.28 mg/dl. Despite continued sedation with Diprivan and treatment with anti-seizure medications, EEG showed prolonged runs of 2 Hz GPDs
concerning for refractory non-convulsive status epilepticus associated with a peak CRP level reaching 52.59 mg/dl. a Serum CRP trend graph. b
Diffusion-weighted magnetic resonance (DW MR) imaging showing numerous punctate foci of diffusion restriction, with corresponding reduced
signal intensity on attenuation diffusion coefficient (ADC), in the cerebral subcortical white matter bilaterally, more in a watershed distribution. c
EEG day 2 showing persistent non-convulsive status epilepticus (generalized periodic discharges (GPDs))

and neurological assessments, together with the relevant
diagnostic (serological, CSF, EEG, and neuroimaging) studies, may help in establishing the diagnosis of this particular
type of inflammatory encephalopathy induced by exaggerated innate immune response.
Role of IL-17 and its related cytokines in BBB
hyperpermeability

Notably, upregulation of the immune responses mediated by Th17 cells and IL-17, typically associated with
auto-inflammatory diseases, is also detected in several
CoV-related infections including SARS-CoV, MERSCoV, as well as severe cases of SARS-Cov-2 [1, 13, 15].
Experimental and human models show activated Th17
cells can produce IL-17, which in turn can induce neurovascular endothelial expression of CCL2 (MCP-1) and

CXCL1, promoting trans-endothelial migration of activated Th17 cells into brain parenchyma [42]. Proinflammatory cytokines such as TNF-α can also augment
Th17 cell adhesion to the cerebral endothelium via upregulating endothelial vascular cell adhesion molecule 1
(VCAM-1) expression [42]. IL-17 excess can also propagate other inflammatory pathways via upregulation of (a)
other pro-inflammatory cytokines (i.e., IL-6, IL-1β, and
TNFα), (b) chemokines (i.e., CCL2 and MIP-2/IL-8), and
(c) pro-inflammatory mediators (i.e., cyclooxygenase-2,
prostaglandin E2, and nitric oxide) [49]. The synergic
crosstalk between IL-17 with other cytokines (i.e., IL-1β
and TNFα) can also augment IL-6 response [49, 50].
This response can, in turn, functionally exhaust T-cells
and promote their apoptosis, which might contribute to
lymphocytopenia associated with increased disease
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activity of COVID-19 [14, 15, 34]. Moreover, human
studies showed that excess IL-17 signaling could also
contribute to neuronal toxicity via activating inflammatory pathways that involve nuclear factor kappa-lightchain enhancer of activated B cells (NFκB) [51].

SARS-CoV-2-associated encephalitis
SARS-CoV has been detected in brain tissue and CSF
[20, 26, 28, 29, 52–59], and there are now isolated reports indicating that SARS-CoV-2-can invade brain [23,
28, 57]. The great similarity between SARS-CoV and
SARS-CoV-2 also supports the neuroinvasive potential
of SARS-CoV-2 [20, 21, 23, 24, 26, 28, 48–52], although
this appears to be a rare phenomenon. Neuroinvasion is
thought to occur via retrograde trans-synaptic dissemination of SARS-CoV-2 from mechanoreceptors and
chemoreceptors in the lung to the medullary cardiorespiratory center [26, 29, 60]. This mechanism may explain the predominance of brain stem involvement
reported in other CoVs-related infections [26, 29]. It also
provides an additional support for the potential neurogenic contribution to the pathophysiology of hypoxemic
respiratory failure [29, 59], independent of the acute
lung inflammatory injury burden on chest imaging [6, 8,
29, 59]. Similar to that of SARS-CoV, ACE2 appears to
serve as the likely functional entry co-receptor for
SARS-CoV-2 [28, 29, 61–64]. ACE2 is widely expressed
in many organs such as in the lung, heart, kidney, intestine, and brain [28]. In the brain, ACE2 is expressed by
glia, neurons, and neurovascular endothelium [28], with
greater expression at the brain stem regions that are
known to influence cardiorespiratory functions such as
the nucleus of the tractus solitarius, paraventricular nucleus, and rostral ventrolateral medulla [29]. We suggest
that the binding affinity of the viral surface spikeglycoprotein (S1) to the endothelial ACE2 may mediate
SARS-CoV-2 entry into the neurovascular endothelia,
potentially causing endotheliopathy and endotheliitis,
similar to those observed in the peripheral vasculature
(Fig. 1) [28, 29, 61]. Moreover, trans-endothelial migration of infected ACE2 expressing CD169+ macrophages
[36] may also contribute to the viral invasion of the
brain. Another potential route of neuro-invasion may involve retrograde transport of viral antigens along the
axons of olfactory sensory neurons, as demonstrated in
mice transgenic for human ACE2 intranasally inoculated
with SARS-CoV [26, 59, 65, 66]. This is consistent with
ACE2’s expression (unclear whether neuronal or nonneuronal type) in human olfactory epithelium [67] and
the widely-held concept that olfactory bulb can serve as
a pivotal CNS sensory effector organ in transporting
neurotropic viral infections [24, 58, 68]. This is supported by the reports of isolated anosmia (at times with
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ageusia) as presenting symptom in some SARS-CoV-2
positive-individuals [10, 69].
Although the underlying bases of SARS-CoV-2 neurovirulence are not fully elucidated, several factors can
differentially influence its effects on the CNS [28].
SARS-CoV-2 may not only directly but also indirectly
injure infected ACE2-expressing CNS resident cells (i.e.,
neurons, glial cells, and endothelial cells), parallel to the
ability of SARS-CoV to induce neuronal injury in mice
transgenic for human ACE2 via mechanisms that do not
involve direct inflammatory responses [66]. We suggest
that some of these mechanisms may involve downregulation of the expression of ACE2 bound to SARS-CoV-2
glycoprotein spike protein (S1) (Fig. 1) [60, 70]. Similar
to the effects observed in the wild-type mice model of
SARS-CoV-induced ARDS-like injury [60, 70, 71],
SARS-CoV-2 infection of the brain may also downregulate ACE2 expression and increase tissue angiotensin II
levels (Fig. 1). These effects may contribute to neurovascular endothelial dysfunction and neuronal dysfunction
(Fig. 1) [60, 70]. ACE2 regulates the RAS via catabolizing
angiotensin II to angiotensin-(1–7), as well as angiotensin I to angiotensin-(1–9). Angiotensin-(1–9) is converted by neutral endopeptidase and angiotensin
converting enzyme to angiotensin-(1–7) [72, 73]. Experimental and human data show that angiotensin-(1–7) exerts vasoprotective effects via the (G protein-coupled
receptor) known as MAS receptor [72, 73]. The angiotensin-(1–7)/MAS receptor pathway can also promote
vasodilation directly or indirectly via upregulating
endothelial telomerase activity [72, 73]. Increased
telomerase activity can, in turn, increase endothelial
eNOS-dependent synthesis of the vasodilator nitric oxide
(NO), which can activate endothelial telomerase activity
in a feed-forward regulatory loop [73]. Thus, SARSCoV-2 may dysregulate the CNS RAS by downregulating
the beneficial angiotensin-(1–7)/MAS receptor pathway
and potentiating the harmful angiotensin converting enzyme/angiotensin II/angiotensin type1 receptor cascade
[73]. These effects can result in hypoperfusion due to
vasoconstriction and endothelial dysfunction, as well as
vascular injury due to inflammation and excessive oxidation (Fig. 1) [64, 74–77].
Moreover, like in SARS-CoV infection [78], the potential role of IgG antibodies specific to spike glycoprotein
S1 (highly immunogenic molecule shared by CoVs) in
promoting neuroinflammation in SARS-CoV-2 infection
is unclear. This may occur via facilitating the entry of
viral spike glycoprotein (S1)-S1 IgG antibody complex
into the host immune cells (potentially including those
in the CNS) following its binding to Fc receptors
expressed on these cells. This phenomenon is known as
an “antibody-dependent enhancement,” which is shown
to potentiate viral spread and replication as well as

Najjar et al. Journal of Neuroinflammation

(2020) 17:231

inflammation [60]. This is consistent with the observations paradoxically associating augmented IgG response
and greater rise in antibody titers with increased severity
and worse clinical outcome [14]. The participation of activated complement cascade, in response to either antibodies production or viral proteins, in the SARS-CoV-2
related CNS injury remains unproven. Up to now, the
evidence of complement activation via classical pathway
involving viral spike glycoprotein (S1)-antibody complex
remains lacking [60]. However, N proteins of SARSCoV-2 are recently shown to activate complement system, via lectin pathway, by binding to serine protease of
the mannose-binding lectin (MBL)-associated serine
proteases (MASPs) [13, 79, 80]. This is supported by the
findings of increased C3 complement deposition in the
lung biopsy samples and higher C5a complement levels
in the sera of individuals with SARS-CoV-2-related
ARDS [13, 79, 80]. Further, like in ARDS-related lung
injury, neurological complications might be also associated with increased levels of activated complement proteins in the injured brain tissue, potentially contributing
to increased inflammatory response and worsening of
neurological sequelae [13]. These proteins may be activated either intrathecally or alternatively in the periphery
before they enter the brain through the disrupted BBB.

Post-infectious CNS autoimmunity
Acute necrotizing encephalopathy (ANE)

COVID-19-related ANE has only been reported once in
the literature [81]. We report an additional case of acute
necrotizing encephalopathy in association with SARSCoV-2 (Fig. 3a); A 23-year-old SARS-CoV-2-positive female presented mainly with severe encephalopathy rapidly progressed to catatonia-like syndrome associated
with vertical nystagmus. There was no concurrent respiratory or any other systemic manifestation. Serological tests were notable for elevated C-reactive protein
(CRP) of 72.3 mg/dl. CSF analysis was completely normal. Coronal (1) and axial (2) fluid-attenuated inversion
recovery (FLAIR)/T2-weighted (T2W) MR images revealed signal hyperintensities of the ventromedial thalami and hippocampi. DWI (3) and attenuation diffusion
coefficient (ADC) (4) images showed slightly increased
signal intensity on DWI but without low signal intensity
on ADC to suggest diffusion restriction. Bilateral
thalamic involvement is highly characteristic for ANE.
Treatment with intravenous immunoglobulin (2 g/kg divided over 5 days) and a 5-day course of intravenous
pulse methylprednisolone (1000 mg/day) resulted in partial improvement of sensorium and ability to follow only
simple commands. Rituximab IV 1000 mg given on hospital day number 21 due to persistent encephalopathy
felt to be immune-mediated. Subsequently, her neurological condition improved and she became alert,
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oriented × three, and able to follow commands with
fluent language. Patient was discharged to an acute
rehabilitation facility on hospital day number 30 and
subsequently went home.
ANE is a rare post-infectious CNS autoimmune disorder
that predominantly affects children but can occur in
adults. It is characterized by acute encephalopathy,
seizures, reduced level of consciousness, and rapid neurological decline [22–25]. It typically follows febrile illnesses,
mainly viral infections [22–25], and results in severe
neurological disability and high mortality (mortality rate ~
30%, particularly when diagnosis and treatment are
delayed) [25]. Neuroimaging studies show a characteristic
multifocal symmetric involvement of white and grey
matter (affecting thalami, periventricular white matter, internal capsule, putamen, brain stem tegmentum, and cerebellum), with consistent thalamic involvement (Fig. 3a) on
T2-weighted, fluid attenuation inversion recovery (FLAI
R), and DWI images [25]. The lack of inflammatory response in the CSF and the affected brain tissue suggest
that this disorder is not inflammatory [22–25]. Parainfectious hypercytokinemia and its related BBB disruption are thought to contribute to the pathophysiology of
ANE [25]. Genetic contribution to the pathogenesis in a
subset of children with ANE is suggested by the reports
occasionally associating ANE with human leukocyte antigen (HLA) DRB/HLA DQB genes and mutations of the
Ran Binding Protein 2 (RANBP2) gene [25].
Acute disseminated encephalomyelitis (ADEM)

Animal and human data connect coronavirus to demyelination diseases [19]. Like in other CoV infections [20],
ADEM-like disorders can be sequelae of COVID-19 (Fig.
3b). We present a case of a 56-year-old SARS-COV-2
positive female admitted for diarrhea and hypoxemic respiratory symptoms that progressed to ARDS necessitating intubation. Notable laboratory findings were CRP of
31 mg/dl (reference range 0.00–0.40), ferritin of 799 ng/
ml (reference range 15–150 ng/ml), D-Dimer of 362 ng/
ml (reference range < 230 ng/ml), and IL-6 of 42 (reference range less < 5 pg/ml). The neurological examination following extubation and cessation of sedative
agents was notable for severe encephalopathy and
quadriplegia. Axial FlAIR MR images (1, 2, 3) demonstrate multiple periventricular white matter hyperintensity lesions, without corpus callosal involvement. There
is no enhancement or restricted diffusion on DWI (4, 5,
6). These findings are consistent with acute disseminated
encephalomyelitis. Patient received a 5-day course of
intravenous pulse methylprednisolone (1000 mg/day)
and tocilizumab 750 mg (8 mg/kg) intravenously. Subsequently, she improved substantially to the point of becoming fully awake and alert with 4/5 power of upper
extremities and 3–4/5 power of lower extremities.
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Fig. 3 Para-infectious autoimmunity. a Acute necrotizing encephalopathy (ANE). A 23-year-old SARS-CoV-2-positive female presented mainly with
encephalopathy progressed to catatonia. C-reactive protein (CRP) was 72.3 mg/dl. CSF analysis was completely normal. Coronal (1) and axial (2)
fluid-attenuated inversion recovery (FLAIR)/T2-weighted (T2W) MR images reveal signal hyperintensities of the ventromedial thalami and
hippocampi. DWI (3) and ADC (4) images show slightly increased signal intensity on DWI but without low signal intensity on ADC to suggest
diffusion restriction. Bilateral thalamic involvement is highly characteristic for ANE. Her neurological condition improved substantially following
immune therapies that included intravenous immunoglobulin, intravenous pulse methylprednisolone, and rituximab. b Acute disseminated
encephalomyelitis (ADEM). A 56-year-old SARS-COV-2 positive female admitted for diarrhea and hypoxemic respiratory symptoms that progressed
to ARDS necessitating intubation. Notable laboratory findings were CRP of 31 mg/dl (reference range 0.00–0.40), ferritin of 799 ng/ml (reference
range 15–150 ng/ml), D-Dimer of 362 ng/ml (reference range < 230 ng/ml), and IL-6 of 42 (reference range less < 5 pg/ml). Neurological
examination was notable for severe encephalopathy and severe quadriplegia. Axial FlAIR MR images (1, 2, 3) demonstrate multiple periventricular
white matter hyperintensity lesions, without corpus callosal involvement. There is no enhancement or restricted diffusion on DWI (4, 5, 6). These
findings are consistent with acute disseminated encephalomyelitis. Patient received a 5-day course of intravenous pulse methylprednisolone
(1000 mg/day) and tocilizumab 750 mg (8 mg/kg) intravenously. She improved substantially to the point of becoming fully awake and alert with
4/5 power of upper extremities and 3–4/5 power of lower extremities. Patient was discharged to an acute rehabilitation facility and then went
home showing a steady neurological improvement

Patient was discharged to an acute rehabilitation facility
and then went home showing ongoing neurological
improvement.
ADEM is an immune-mediated, generally monophsic,
demyelinating disorder. It frequently occurs in children
less than 10 years of age [82, 83]. Neuroimaging shows
reversible lesions multiple white matter lesions of the
brain and spinal cord, with frequent involvement of the
subcortical gray matter structures [19, 83]. Clinically, it
is characterized by an acute-onset encephalopathy
associated with multiple focal neurologic deficits, often
preceded by a febrile prodromal illness or recent vaccination [83]. The pathophysiology of post-COVID-19
ADEM is likely similar to that proposed for other postinfectious ADEM. It involves adaptive (e.g., mainly T
and B cells, with some plasma cells) and innate immunity (circulating granulocytes, macrophages, monocytes,
and activated microglia in the cortex) [82, 83]. Humoral
immunity involving antibodies targeting myelin
oligodendrocyte glycoprotein (MOG) may be also
contributory [82, 83].

Seizures
Seizures are common in SARS-CoV-2 infection (Fig. 2)
[10, 84]. We report a case of new-onset seizures in a 71year-old SARS-CoV-2 positive female who presented
with altered mental status and respiratory difficulty
necessitating intubation. While on sedation, she was
witnessed to have a convulsive seizure concurrent with

CRP elevating from 16.64 to 30.28 mg/dl. Despite
continued sedation with Diprivan and treatment with
several anti-seizure medications, EEG showed prolonged
runs of 2 Hz generalized epiletiform discharges (GPDs)
concerning for non-convulsive status epilepticus associated with a peak CRP level reaching 52.59 mg/dl. Brain
MRI-DWI showed numerous punctate foci of diffusion
restriction with corresponding reduced signal intensity
on ADC in the cerebral subcortical white matter,
bilaterally mainly affecting watershed distribution,
consistent with foci of cerebral ischemia. Subsequent
complete seizure control resulted in a slow but steady
improvement of the neurological condition to the point
she became fully alert, communicative, and able to move
all extremities with moderate weakness. Unfortunately,
she died 1 week after she was discharged to rehabilitation facility.
CNS inflammation associated with innate immune
activation induced by viral replication and excess proinflammatory cytokine release can lower seizure
thresholds and promote epileptogenesis [85, 86]. Proinflammatory cytokines are shown in animal models to
increase seizure susceptibility via multiple mechanisms
involving neuronal hyperexcitability and pathological
synaptic alterations; the findings of neuronal excitability
and inflammation have been extensively reviewed in
(2013) [85]. Further, seizures can result from SARSCoV-2-associated neurological complications such as ischemic or hemorrhagic strokes [22, 87].
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Cerebrovascular events
Greater incidence of strokes, ischemic or hemorrhagic,
is reported in individuals, commonly middle-aged and
elderly, with SARS-CoV-2 [10, 22, 27, 74, 87, 88] (Figs.
4a and 5) parallel to that in SARS-CoV [10, 22, 27, 74,
87, 88]. Notably, many of these reported strokes have
concurrent vascular risk factors for stroke such as hypertension, hyperlipidemia, diabetes mellitus, smoking, and
prior strokes [74]. However, the reported increase in
large vessel strokes among individuals younger than 50
years of age and without prior significant vascular risk
factors suggests additional pathoetiologies that are
specific to SARS-CoV-2. Hyper-inflammation-mediated
endotheliopathy (discussed in encephalopathy section
and depicted in Fig. 1) and consumption hypercoagulopathy are often implicated [31, 89]. Indeed, greater Ddimer and fibrin/fibrinogen degradation product (FDP)
levels, as well as longer prothrombin time (PT), are
noted among non-survivors compared to survivors with
SARS-CoV-2 infection [90]. Hypercoagulopathy is likely
related to sepsis [88, 91, 92], cytokine storm, or immune
dysregulation [93]. Under these conditions, crosstalk
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between systemic inflammation, endothelial dysfunction,
and coagulation cascades can play a key role in the
pathogenesis of thrombo-embolic events [91, 92]. Severe
sepsis invariably involves coagulation activation via
multiple mechanisms involving aberrant upregulation of
tissue factor expression in vascular endothelial cells and
circulating cells such as monocytes, as well as inhibition
of anticoagulant pathways such as fibrinolytic system
and protein C-protein S-thrombomodulin system [92–
94]. Further, surges in pro-inflammatory cytokines (e.g.,
TNF-alpha, IL-1, and IL-6) and immune dysregulation
following extensive tissue injury can additionally activate
coagulation pathways [92–96]. Antiphospholipid antibodies, such as anticardiolipin (Figs. 5 and 6) and
anti–β2-glycoprotein I (IgA and IgG) antibodies, can also
contribute to the pathophysiology of coagulopathy
(increased prothrombin time and elevated levels of Ddimer and FDD) in some COVID-19-related strokes
[89]. Reduced cerebral blood flow and ischemia may be
also directly related to alteration of the RAS activity
caused by downregulation of endothelial ACE2 expression in response to SARS-CoV-2 S1 binding to

Fig. 4 COVID-19 related stroke and posterior reversible encephalopathy syndrome. a Ischemic and hemorrhagic infarcts. A 73-year-old female
presented with respiratory difficulty related to COVID-19 necessitating intubation. Following extubation and cessation of sedation, she remained
persistently somnolent and was noted to have weakness of all extremities. Initial NIHSS was 12. Past medical history was notable for coronary
artery disease, congestive heart failure, hypertension, and diabetes mellitus. Laboratory findings were notable for slightly elevated CRP (1.2 mg/dl)
and significant elevation of ferritin (754 ng/ml) and D-Dimer (4184 ng/ml). Axial FlAIR MR images (1, 2, 3) demonstrate multifocal areas of signal
abnormalities involving both cerebellar hemispheres, right occipital lobe, and right frontal lobe, with a hemorrhagic component (mostly involving
right frontal region). Smaller foci of signal abnormality were present in the parietal cortices and centrum semiovale. Axial DWI (4, 5, 6) display
multifocal areas of diffusion restriction consistent with acute ischemia. Hypercoagulopathy is the likely etiology of strokes. The patient had been
on clopidogrel and low dose enoxaparin (DVT prophylaxis) before her stroke. Her neurological condition improved substantially with only
minimal residual left hemiparesis and mild ataxia were noted at the first follow-up visit, which was several weeks after hospital discharge. b
Posterior reversible encephalopathy syndrome (PRES). A 43-year-old SARS-CoV-2-positive female presented with respiratory distress that
progressed rapidly to ARDS. Serological findings were notable for elevation of CRP (32 mg/dl), ferritin (259 ng/ml), and D-Dimer (7643 ng/ml).
Post-extubation, she remained lethargic despite discontinuation of sedatives. She was slightly hypotensive to normotensive. The neurological
exam showed lethargy, dysconjugate gaze, and triplegia. CSF analysis was entirely normal. Oligoclonal bands were absent. IgG index 0.8 (normal
< 0.7). Notably, the neurological recovery was slow and concurrent with the return of serum inflammatory markers to normal levels. T2W MR
images (1, 2) demonstrate bilateral parietal, and to a lesser extent frontal lobe, signal hyperintensities consistent with vasogenic edema. There is
no corresponding high signal intensity on DWI (3, 4) or low signal intensity on ADC (5, 6) to suggest diffusion restriction. The findings are
suggestive of PRES associated with high circulating markers of inflammation and coagulation pathways activation. The patient exhibited a slow,
but steady, recovery concurrent with the reduction of serum levels of the inflammatory markers. This recovery was further enhanced by a 3-day
course of intravenous pulse methylprednisolone (1000 mg/day). She was discharged home with only mild cognitive and motor impairment
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Fig. 5 Strokes and concurrent subacute inflammatory necrotizing response. An 84-year-old SARS-CoV-2-positive female presented solely with
rapidly progressive encephalopathy and neurological decline associated with mild left sided hemiparesis and left sided-visuospatial neglect. There
were no concurrent respiratory or any other systemic symptoms. Serological findings were remarkable for CRP of 5.89 mg/dl, ferritin of 383 ng/dl,
and D-Dimer of 852 ng/dl, and positive anticardiolipin IgM antibodies of 32.CSF analysis revealed elevated protein (153 mg/dl), normal glucose,
and a cell count of three nucleated cells. Computed tomography (CT) scan (1, 2) shows prominent vasogenic edema nearly involving the entire
right temporal lobe (green arrow), watershed subacute-chronic ischemic infarction of the right anterior frontal (red arrow), and old cystic
encephalomalacia of the left parietal (blue arrow). 3D CT angiogram (3) shows normal flow through the right middle cerebral artery without
evidence of large vessel occlusion or high grade stenosis. Axial T1-(4) and T1-weighted post-gadolinium [axial (5) and sagittal (6)] MR images
show diffuse gyral cortical enhancement with subcortical areas of necrosis involving right temporal lobe (green arrow). Axial FLAIR (7) and axial
T2W (8) MR images reveal signal hyperintensities with gyral swelling nearly involving the entire right temporal lobe and insula (green arrow)
associated with petechial hemorrhage, best seen on the gradient echo image (9). In addition, there are subacute-chronic infarct of the right
anterior lateral frontal lobe (red arrow) and a wedge-shaped old cystic encephalomalacia of the left parietal lobe (blue arrow). Following
treatment with tocilizumab 560 mg (4 mg/kg), the patient exhibited significant improvement of the mental status and left hemiparesis and was
subsequently discharged home. Hypercoagulopathy is the likely etiology of the right frontal and left parietal strokes. The appearance of the
concurrent right temporal lobe and insula abnormalities is highly suggestive of an independent subacute inflammatory-necrotizing, rather than
ischemic, process. This is supported by the findings of completely patent right middle cerebral artery, diffuse gyral swelling and enhancement
with concurrent prominent subcortical vasogenic edema and necrosis, and significantly elevated CSF protein. Although the precise mechanisms
underlying vasogenic edema and necrosis remain unclear, we suggest that localized hyper-inflammation provoked by exuberant innate immune
response (CNS cytokine response) might be pathogenetically relevant. Direct viral neuroinvasion and involvement of the neurovascular
endothelial cells were subsequently excluded by the brain biopsy from the right temporal necrotizing lesion

endothelial ACE2 (Fig. 1) [64, 74–77, 88]. This downregulation may accelerate atherosclerosis process in preatherosclerotic conditions such as diabetes [97, 98].

Moreover, the proposed direct SARS-CoV-2 infection of
the endothelial cells of the cerebral microvasculature
may prove to be relevant to the pathophysiology of
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Fig. 6 Inflammatory vasculopathy. A 45-year-old SARS-CoV-2-positive man presented chiefly with encephalopathy and aphasia, without
concurrent respiratory or any other systemic symptoms. Serum levels of inflammatory makers (CRP; 152.4 mg/dl, ESR; 91 mm/h) and D-Dimer (464
mg/dl) were elevated. Anticardiolipin IgM antibodies were 52.3 (normal range 0–12.5). Past medical history is notable for diabetes and
hypertension. Axial FLAIR (1, 4) MR images show gyriform signal hyperintensity of the left paramedian frontal lobe and genu of the corpus
callosum with corresponding high signal intensity on DWI (2, 5) and low signal intensity on ADC (3, 6) compatible with an acute ischemia. The
maximum intensity projection (MIP) of CT angiogram demonstrates irregular areas of narrowing of the left A1 and M1 segments. These findings
are consistent with inflammatory vasculopathy, likely related to the interplay among systemic inflammation, immune dysregulation, and
anticardiolipin antibodies. Direct infection of the endothelial cells and its contribution to the vascular irregularity of the affected vascular
segments cannot be excluded. The patient received tocilizumab 8 mg/kg intravenously and a 5-day course of intravenous pulse
methylprednisolone (1000 mg/day). He was discharged to a subacute rehabilitation facility with mild improvement of aphasia and
cognitive deficit

strokes. Other non-specific etiologies may include
thrombocytopenia and hemodynamic instability associated with cardiac dysfunction as well as erratic blood
pressure fluctuations and that are common in severe
and critical cases of COVID-19 [74].
Posterior reversible encephalopathy syndrome (PRES) is
increasingly reported in normotensive individuals with
COVID-19 associated with systemic inflammation, immune dysregulation, and coagulopathy (Fig. 4b). PRES is
typically characterized by diffuse encephalopathy associated with headache, visual impairment, seizures, and focal
neurological deficits. Hypertension is a frequent comorbidity in individuals with PRES and thought to play a
pivotal role in its pathophysiology [99]. The mechanisms
underlying PRES in normotensive COVID-19-positive
patients, however, are not completely celar [99, 100]. Its
association with high circulating markers of inflammation
and coagulopathy (Fig. 4b) suggests that hyperinflammation-related neurovascular endotheliopathy may
also contribute to the pathophysiology of PRES. This, in
turn, can lower cerebral vasoregulatory capacity, increase
BBB permeability, and reduce cerebral perfusion, leading
to vasogenic edema (Figs. 1, 4b, and 5) [99, 100].
Lastly, inflammatory vasculopathy may contribute to
cerebrovascular events in COVID-19. Figure 6 depicts a
COVID-19 patient who presented with encephalopathy
and aphasia associated with systemic inflammation and
elevated levels of anticardiolipin antibodies. Radiographic findings were suggestive of inflammatory

vasculopathy of left A1 and M1 segments. Although the
interplay among systemic inflammation, immune dysregulation, and anticardiolipin antibodies might have contributed to the vasculopathy in this patient [95, 101],
more data are needed to establish this causation. Direct
viral infection of the endothelial cells of the affected
vascular segments cannot be excluded [61].

Psychiatric, cognitive, and neurological sequelae
Neurologists and psychiatrists need to be aware of the
potential cognitive, neurological, and psychiatric sequelae of COVID-19 pandemic [102], similar to those noted
among survivors of Spanish influenza pandemic and
SARS-CoV epidemic [103]. Psychosis, catatonia, hypersomnolence, and Parkinsonism characterize encephalitis
lethargica that followed Spanish influenza pandemic.
The estimated cumulative incidence of psychiatric sequelae concurrent with SARS-CoV is about 59% [104];
these include depression, post-traumatic stress disorder
(PTSD), panic disorder, and obsessive-compulsive
disorder [105]. We suspect that the persistence of CNS
aberrant innate immune signaling provoked by SARSCoV-2 might contribute to the pathophysiology of these
disorders. The human and animal data linking innate
immune responses in the brain and the periphery to
psychiatric illnesses have been previously reviewed by
our group, including psychiatric illnesses and neuroinflammation (2013) [46], neurovascular dysfunction and
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BBB hyperpermeability in schizophrenia (2017) [40], and
depression (2013) [41].

Clinical relevance of recurrent mutations in SARSCoV-2
Emerging data has confirmed the emergence of about 198
filtered recurrent mutations of SARS-CoV-2, with a
greater number of recurrent mutations involved regions
encoding Nsp6, Nsp11, Nsp13, and S protein, likely resulting from continuing spread and adaptation of the virus to
the human host [106]. Some new strains may possess differential virulence and pathogenicity relevant to their abilities to infect host cells, invoke systemic excess innate
immune response-dependent hyper-inflammation-related
cellular, and molecular changes (such as those associated
with endotheliopathy, vasculopathy, and coagulopathy),
adversely affect host protective adaptive immune cells pivotal for viral clearance, and cause neurological complications. Although the viral genomic diversity is expected to
increase over time, its potential impact on the emergence
of additional clinical phenotypes of SARS-CoV-2 infection
and the efficacy of future vaccinations remains uncertain.
Conclusions
COVID-19, a highly infectious pandemic caused by
SARS-CoV-2, is frequently associated with neurological
complications, particularly among those with severe and
critical illnesses. This review highlights the central
nervous complications associated with COVID-19. It
also provides a theoretical integration of clinical and
experimental data to elucidate the pathogenesis of these
disorders. Specifically, how systemic hyper-inflammation
provoked by maladaptive innate immunity may impair
neurovascular endothelial function, disrupt BBB, activate
CNS innate immune signaling pathways, and induce
para-infectious autoimmunity, potentially contributing
to the CNS complications associated with SARS-CoV-2
infection. Direct viral infection of the brain parenchyma
causing encephalitis, possibly with concurrent neurovascular endotheliitis and CNS RAS dysregulation, is also
reviewed.
Large-cohort studies integrating findings from clinical,
neuroimaging, CSF assays, and post-mortem brain tissue
studies can shed more light on the neuroinvasive propensity, neurotropism, and neurovirulence of SARSCoV-2. Future research should also focus on exploring
factors that regulate differential CNS innate immune response, including cytokine network, to SARS-CoV-2 infection. Those include host protective immune signaling
pathways pivotal to eliminate replicating viruses, protect
uninfected cells, and prevent harmful autoimmunity.
Findings from such studies would then guide the development of molecularly targeted immune-modulatory
agents to promote meaningful neurological recovery.
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